Early Use of High-Efficacy Anti-CD20 Therapy Ofatumumab in Relapsing MS

Williams describes how the shift toward early use of high-efficacy therapy in relapsing MS has brought ofatumumab, an at-home, subcutaneous anti-CD20 agent, into treatment discussions at the start of the disease course.

Williams outlines how active disease features, lifestyle needs, and prior experience with injectable therapies inform selection of ofatumumab as a high-efficacy, self-administered option for patients with relapsing multiple sclerosis.

Williams explains that at-home, once-monthly ofatumumab is generally well received by patients with relapsing MS, offering convenience for those with active work and family lives while addressing concerns about injections and treatment scheduling.

Williams describes long-term treatment success with ofatumumab in relapsing MS, noting that ASCLEPIOS trial and extension data support sustained reductions in relapse rates, MRI lesions, and confirmed disability progression.

Ensuring safety over the course of high-efficacy therapy remains a central concern in the management of relapsing multiple sclerosis (MS).

Shared decision-making has become a foundational element of contemporary multiple sclerosis (MS) care, particularly as the number of available disease-modifying therapies has expanded.

As anti-CD20 therapies become entrenched in the treatment paradigm for multiple sclerosis (MS), questions about their long-term use, sequencing, and broader impact on patient care are moving to the forefront.